Equities

Capricor Therapeutics Inc

Capricor Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)18.10
  • Today's Change-1.44 / -7.37%
  • Shares traded1.33m
  • 1 Year change+546.43%
  • Beta4.0188
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Capricor Therapeutics Inc grew revenues 886.81% from 2.55m to 25.18m while net income improved from a loss of 29.02m to a smaller loss of 22.29m.
Gross margin--
Net profit margin-102.93%
Operating margin-110.50%
Return on assets-66.31%
Return on equity-392.69%
Return on investment-208.71%
More ▼

Cash flow in USDView more

In 2023, Capricor Therapeutics Inc increased its cash reserves by 53.02%, or 5.09m. Cash Flow from Financing totalled 25.58m or 101.60% of revenues. In addition the company used 25.60m for operations while cash from investing totalled 5.11m.
Cash flow per share-0.8912
Price/Cash flow per share--
Book value per share0.3596
Tangible book value per share0.3596
More ▼

Balance sheet in USDView more

Capricor Therapeutics Inc has a Debt to Total Capital ratio of 22.69%, a lower figure than the previous year's 123.62%.
Current ratio1.37
Quick ratio--
Total debt/total equity0.2935
Total debt/total capital0.2269
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.